Copay accumulator programs, which exclude the benefit of manufacturer patient assistance from annual maximum out‐of‐pocket costs, shift costs for expensive oncology drugs from plans to patients. Legislation is ongoing to protect patients from these potentially harmful re‐definitions of cost‐sharing.
No takes yet. Share an insight, caveat, or question.
Baker et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: